Abstract 6119
Background
Cancer nursing is required to identify potential advances in nursing practice, assess their relevance for ones own particular clinical situation, gather opinion on any potential change in practice (both locally and farther afield), integrate this into practice, evaluate success and then disseminate the learning from this process. Until relatively recently this process could be reasonably laborious and slow moving. However, the advent of social media sites and software and their use in nursing has streamlined this process making the gathering, group analysis and dissemination of clinical information faster and more intuitive. This study considers the authors own experience in using two social media sites (Twitter and Facebook) to gather and share clinical infomation as part of the UK Oncology Nursing Society and when setting up a new Members Interest Group for UK Lead Cancer Nurses.
Methods
This piece describes the use of Twitter and Facebook group as a professional tool to -: 1) Gather cancer nursing opinion on a particular subject (case study - Streamlining MDT Working in England and the contrubution of specialist Nursing) - potentially a ’digitall Delphi Technique’ using Twitter and Facebook 2) Build group cohesion, ask clinical questions, share information and practice and build relationships within a newly established UK group of Lead Cancer Nurses. The experiences of UKONS members of using social media professionally will be gathered, the clinical effectivenes of using social media to gather nursing opinion on a particular nursing problem (streamlining MDT working) will be analysed.
Results
The experiences of cancer nurses in using social media in professional settings will be presented as part of an overall narrative and key themes will be presented and discussed Number and range of responses to a clinical question posed on social media will be presented with consideration of how effective a tool Twitter is in gathering clinical opinion and driving improvement. Ths will be presented numerically and graphically.
Conclusions
The positive impact of the professional use of social media will be presented. Potential uses and fine tuning of these tools in cancer nursing will be considered Potential pitfalls and negative effects will also be considered.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5368 - Durvalumab and Paclitaxel Combination for treatment of metastatic triple negative breast cancer is safe with very promising efficacy
Presenter: Hazem Ghebeh
Session: Poster Display session 3
Resources:
Abstract
1520 - A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Presenter: Daan Hurkmans
Session: Poster Display session 3
Resources:
Abstract
1603 - Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small-cell lung cancer (NSCLC) and urothelial carcinoma (UC)
Presenter: Byoung Cho
Session: Poster Display session 3
Resources:
Abstract
3922 - Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs
Presenter: Aaron Hansen
Session: Poster Display session 3
Resources:
Abstract
2408 - Immune checkpoint inhibitors (ICIs) as “chemotherapy (Ctx) sensitization” strategy in advanced solid tumors
Presenter: Francisco Javier Ros Montana
Session: Poster Display session 3
Resources:
Abstract
3612 - Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers
Presenter: Peey Sei Kok
Session: Poster Display session 3
Resources:
Abstract
3827 - Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies
Presenter: Michael Migden
Session: Poster Display session 3
Resources:
Abstract
2120 - A burst of highly differentiated CD4 TL identifies a subset of fast progressors, and correlates with hyperprogressive disease in NSCLC patients treated with ICI
Presenter: Hugo Arasanz
Session: Poster Display session 3
Resources:
Abstract
4254 - Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): a French nationwide retrospective cohort (UNIVOC Study)
Presenter: Christos Chouaid
Session: Poster Display session 3
Resources:
Abstract
1084 - Dissociated responses in patients with metastatic solid tumors treated with immunotherapy
Presenter: Pauline Vaflard
Session: Poster Display session 3
Resources:
Abstract